Fig. 2

ARL3 expression level was associated with the prognosis of glioma patients and the response to chemo- and radio-therapy. a Kaplan–Meier analyses to evaluate the correlation between ARL3 expression and the survival of glioma patients (low, n = 29; high, n = 17; P = 0.0171, with the log-rank test). Data from the TCGA (b, RNA-seq; low, n = 262; high, n = 405; P < 0.0001, with the log-rank test), CGGA (c, RNA-seq; low, n = 161; high, n = 149; P < 0.0001, with the log-rank test) and REMBRANDT (d, microarray; low, n = 214; high, n = 183; P < 0.0001, with the log-rank test) datasets indicated that lower ARL3 expression was correlated to poorer prognosis of glioma patients. e–g Data from the TCGA (b, RNA-seq; low, n = 297; high, n = 228; P = 0.0299, with the log-rank test), CGGA (c, RNA-seq; low, n = 55; high, n = 29; P = 0.0086, with the log-rank test) and REMBRANDT (d, microarray; low, n = 109; high, n = 72; P = 0.0198, with the log-rank test) datasets indicated that reduced ARL3 expression was associated with unfavorable prognosis in GBM patients. h Kaplan–Meier analysis of survival of glioma patients treated with radiotherapy from CGGA (RNA-seq, low, n = 102; high, n = 105; P < 0.0001, with log-rank test). i Kaplan–Meier analysis of the survival of GBM patients treated with radiotherapy from the CGGA according to ARL3 expression (RNA-seq, low, n = 52; high, n = 28; P = 0.0064, with the log-rank test). j Kaplan–Meier analysis of the survival of glioma patients treated with chemotherapy from the CGGA according to ARL3 expression (RNA-seq, low, n = 82; high, n = 105; P < 0.0001, with the log-rank test). k Kaplan–Meier analysis of the survival of primary GBM patients treated with chemotherapy from the CGGA (RNA-seq, low, n = 34; high, n = 18; P = 0.0121, with the log-rank test)